Cubicin® (daptomycin for injection) Rx only
CUBICIN contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of
CUBICIN (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following Gram-positive microorganisms (see also DOSAGE AND ADMINISTRATION):
Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis and Enterococcus faecalis
(vancomycin-susceptible strains only). Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms (see CLINICAL STUDIES).
Daptomycin is not indicated for the treatment of pneumonia.
Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. Empiric therapy may be initiated while awaiting test results. Antimicrobial therapy should be adjusted as needed based upon test results.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Published Studies Related to Cubicin (Daptomycin)
Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. [2010.06.15]
BACKGROUND: The objective of this analysis was to evaluate the relationship between daptomycin exposure and the probability of an elevation in the creatine phosphokinase (CPK) level (hereafter, "CPK elevation") in patients with Staphylococcus aureus bacteremia with or without infective endocarditis... CONCLUSIONS: This analysis demonstrated that a daptomycin C(min) 24.3 mg/L was associated with an increased probability of a CPK elevation. Clinical trials registration. Clinical trials.gov NCT00093067 .
Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. [2009.07]
OBJECTIVES: Two randomized Phase I studies in separate populations of healthy adult volunteers investigated the pharmacokinetics, safety and tolerability of daptomycin (Cubicin; Novartis Pharma AG, Basel, Switzerland) administered as a 2 min intravenous (iv) injection, relative to the currently licensed 30 min iv infusion... CONCLUSIONS: The similar pharmacokinetic and safety profiles of the two administration regimens suggest that the 2 min iv injection may be a convenient treatment option for both patients and healthcare professionals.
Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. [2009.05]
OBJECTIVES: Administering outpatient parenteral antimicrobial therapy in the community setting (CoPAT) is becoming more common with the increasing emphasis on controlling costs. However, few controlled trials have evaluated this treatment modality... CONCLUSIONS: With proper monitoring, stable patients can complete treatment for SAB/IE as outpatients in the community setting. Daptomycin is an appropriate option for this setting.
The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. [2009.03]
BACKGROUND: Results from previous trials suggest that daptomycin may result in faster clinical improvement than penicillinase-resistant penicillins or vancomycin for patients with complicated skin and skin structure infections. OBJECTIVE: The objective was to evaluate whether daptomycin treatment of cellulitis or erysipelas would result in faster resolution compared with vancomycin... CONCLUSIONS: There was no difference in the rate of resolution of cellulitis or erysipelas among patients treated with daptomycin or vancomycin. Daptomycin 4 mg/kg once daily appeared to be effective and safe for treating cellulitis or erysipelas.
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. [2008.12]
OBJECTIVES: In a prospective, randomized trial, daptomycin was non-inferior to standard therapy for Staphylococcus aureus bacteraemia and right-sided endocarditis. Since rates of infection due to methicillin-resistant S. aureus (MRSA) infection are increasing and treatment outcomes for bacteraemia caused by MRSA are generally worse than those observed with methicillin-susceptible S. aureus bacteraemia, clinical characteristics and treatment results in the trial's pre-specified subset of patients with MRSA were analysed... CONCLUSIONS: Daptomycin was an effective alternative to vancomycin/gentamicin for MRSA bacteraemia or right-sided endocarditis.
Clinical Trials Related to Cubicin (Daptomycin)
Phase 4 Efficacy and Safety Study of CubicinŽ With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE) [Terminated]
multicenter, randomized, double blind study to describe the safety and efficacy of
daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination
therapy in the treatment of SAIE
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty [Terminated]
This study will evaluate the safety and effectiveness of daptomycin, an antibiotic compared
to another one which is vancomycin when given around the time of joint replacement surgery.
Vancomycin is recommended for perioperative prophylaxis in methicillin resistant
Staphylococcus aureus (MRSA) colonized patients undergoing primary total joint arthroplasty.
Daptomycin has not been recommended for this indication but it is FDA approved for treatment
of MRSA blood stream and skin and soft tissue infections. Data collected during this study
may support the use of daptomycin for this indication and may also be used for other
research purposes that have not yet been specified.
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease [Completed]
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin [Active, not recruiting]
The purpose of this study is to understand how an antibiotic, rifampin, may change the blood
levels of another antibiotic, daptomycin, in the body. In addition, the effect of
polymorphisms in P-glycoprotein (a protein involved in the removal of daptomycin from the
body) on the blood levels of daptomycin will be evaluated. The hypotheses are that rifampin
will decrease the blood levels of daptomycin and that the effect will be greater for certain
Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) [Completed]
Daptomycin is an antibiotic that is affective against many strains of antibiotic resistant
microorganisms. This antibiotic would be appropriate for use in the intensive care unit
(ICU) considering the severity of illness and high risk for infection within this hospital
environment. While in the ICU, patients may develop acute renal failure. Approximately 75%
of ICU patients who develop acute renal failure will require some form of renal replacement
therapy until their kidneys recover. Continuous hemodialysis is becoming one of the most
common forms of dialysis in the ICU as it is a gentle type of dialysis provided over longer
periods of time. The current data demonstrating the ability of continuous hemodialysis to
remove daptomycin from the body is derived from in-vitro trials. The purpose of this trial
is to determine the extent of daptomycin removal from critically ill patients receiving
continuous hemodialysis. Findings from this trial will be used to develop new dosing
recommendations for daptomycin in continuous hemodialysis.
Reports of Suspected Cubicin (Daptomycin) Side Effects
Eosinophilic Pneumonia (49),
Blood Creatine Phosphokinase Increased (38),
Blood Creatinine Increased (21),
Drug Ineffective (18),
Renal Failure Acute (17),
Drug Interaction (14), more >>
Page last updated: 2010-10-05